Pharmacoeconomics of sedation in the ICU.
Despite considerable information on the pharmacotherapy of sedation in the ICU, there is little published on the pharmacoeconomics of sedation in patients who are critically ill. The purpose of this article is to discuss the various components that contribute to the cost of treating the agitated ICU patient and to critically review the articles published since 2000 that evaluated costs and cost-effectiveness in ICU patients receiving drugs for agitation and/or pain. Clinicians should look beyond the acquisition cost of a sedative and include the effect of sedatives on the cost of care when selecting the most appropriate sedative.
Dasta
Joseph F
JF
The Ohio State University, College of Pharmacy, Columbus, OH, USA. jdasta@mail.utexas.edu
Kane-Gill
Sandra
S
D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics*; D016292:Procedural Sedation / Q000191:economics; D003362:Cost-Benefit Analysis; D003422:Critical Care / Q000191:economics / Q000379:methods; D017850:Economics, Pharmaceutical; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics*; D007362:Intensive Care Units / Q000191:economics*; D010146:Pain / Q000188:drug therapy / Q000191:economics; D012121:Respiration, Artificial / Q000191:economics
D000701:Analgesics, Opioid; D006993:Hypnotics and Sedatives